• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences to Present at 3rd Annual Regen Med Investor Day

March 18, 2015 By Celyad

Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of specialized cell therapies, today announced that Chief Executive Officer Christian Homsy will present at the 3rd Annual Regen Med Investor Day, being held Wednesday, March 25, 2015 in New York City.

Dr. Homsy will present at 10:20 a.m. ET / 3:20 p.m. CET to attending investors. During his presentation, Dr. Homsy will discuss Cardio3 BioSciences’ ongoing clinical development programs in cardiology and immuno-oncology.

Details of the Cardio3 BioSciences presentation are as follows:

  • Event: ARM’s Regen Med Investor Day
  • Date: March 25, 2015
  • Time: 10:20 – 10:35 a.m. ET
  • Location: Metropolitan Club, One East 60th Street, New York, NY 10022

At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference as well as on the company’s website in the event section: http://www.c3bs.com/en/events . 

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy